griffithsin
grft
amino
acid
lectin
identifi
red
marin
alga
griffithsia
sp
mori
et
al
structur
character
grft
show
domain
swap
homodim
six
carbohydr
bind
site
bind
termin
mannos
residu
glycan
hiv
envelop
protein
moulaei
et
al
xue
et
al
ziolkowska
et
al
subsequ
function
character
grft
demonstr
potent
hiv
inhibitor
minim
toxic
vitro
vivo
barton
et
al
emau
et
al
kouokam
et
al
mori
et
al
okeef
et
al
grft
display
picomolar
valu
inhibit
laboratori
primari
isol
shown
stabil
activ
macaqu
vagin
fluid
emau
et
al
ferir
et
al
mori
et
al
investig
grft
safeti
profil
reveal
although
bind
human
squamou
epitheli
layer
peripher
blood
mononuclear
cell
cell
tissu
exhibit
signific
inflammatori
respons
expos
grft
grft
retain
picomolar
level
antivir
activ
kouokam
et
al
studi
topic
deliveri
grft
murin
model
infect
show
grft
treatment
safe
efficaci
okeef
et
al
studi
system
deliveri
grft
also
show
good
safeti
profil
rodent
model
minim
chang
spleen
liver
size
coincid
patholog
chang
barton
et
al
grft
favour
safeti
profil
potent
broad
spectrum
antivir
activ
promot
develop
hiv
microbicid
zeitlin
et
al
develop
grft
hiv
topic
microbicid
requir
product
system
make
bulk
quantiti
grft
avail
formul
character
grft
express
use
multipl
recombin
system
includ
e
coli
plant
system
giomarelli
et
al
hahn
et
al
okeef
et
al
vafae
et
al
express
grft
use
e
coli
system
perform
modest
success
cultur
grown
shake
flask
abl
produc
mg
solubl
grft
per
litr
major
protein
form
insolubl
inclus
bodi
optim
e
coli
express
system
use
fermentor
allow
product
mg
grft
per
litr
media
giomarelli
et
al
initi
invest
fermentor
system
repres
signific
upfront
manufactur
cost
necessit
remov
bacteri
endotoxin
algal
protein
grft
ideal
candid
express
recent
grft
demonstr
stabli
express
chloroplast
nicotiana
tabacum
vafae
et
al
commonli
grft
express
transient
nicotiana
benthamiana
use
express
system
recombin
tobacco
mosaic
viru
rtmv
express
system
fuqua
et
al
hahn
et
al
okeef
et
al
vafae
et
al
largest
bodi
publish
work
grft
product
perform
use
rtmv
n
benthamiana
report
planta
express
level
rang
gkg
fresh
weight
plant
materi
purif
method
yield
total
express
grft
recent
report
effort
optim
origin
purif
process
bulk
manufactur
grft
laminar
tissu
n
benthamiana
use
express
vector
new
process
abl
drastic
improv
recoveri
grft
yield
total
express
grft
fuqua
et
al
okeef
et
al
updat
purif
method
pilot
kilogram
quantiti
plant
biomass
assur
robust
rel
simpl
product
methodolog
establish
grft
prior
appli
cgmp
method
eventu
clinic
applic
fuqua
et
al
combin
yield
stabil
establish
purif
analyt
protocol
appli
manufactur
grft
provid
valuabl
exampl
understand
complex
challeng
pmp
industri
scale
toward
develop
hiv
microbicid
one
primari
challeng
move
laboratori
scale
product
bulk
product
regulatori
requir
involv
manufactur
process
protein
product
qualif
therapeut
protein
produc
plant
system
approv
regulatori
author
none
produc
leaf
tissu
regulatori
framework
product
recombin
pharmaceut
plant
exist
draft
form
littl
decad
ago
moreov
industri
still
infanc
draft
guidanc
base
exist
knowledg
experi
regul
pharmaceut
product
mammalian
microbi
cell
lack
specif
relat
use
whole
plant
principl
good
manufactur
practic
gmp
abl
extrapol
mammalian
microbi
technolog
technolog
practic
may
work
well
product
produc
plant
cell
cultur
whole
system
howev
introduc
new
separ
challeng
fischer
et
al
situat
caus
develop
two
diverg
product
pathway
plant
cell
cultur
system
whole
plant
system
plant
cell
cultur
technolog
advantag
allow
enough
similar
concept
process
mammalian
microbi
express
system
clearer
straightforward
regulatori
pathway
facil
use
whole
plant
technolog
work
regul
make
clear
requir
handl
new
issu
seed
bank
instead
cell
bank
fischer
et
al
therefor
mechan
process
qualif
plant
express
must
develop
thorough
understand
regulatori
requir
review
discuss
regulatori
aspect
involv
express
grft
use
rtmv
technolog
outlin
plan
qualif
virion
plasmid
bank
includ
stabil
monitor
requir
qualif
drug
substanc
common
technolog
use
protein
product
although
regulatori
path
pmp
versu
mammalian
insect
cell
microbi
system
may
exhibit
differ
basic
tenet
gmp
hold
true
across
board
pharmaceut
requir
manufactur
releas
accord
cgmp
effort
provid
guidanc
futur
pmp
includ
certif
analysi
cofa
grft
stabil
plan
overview
techniqu
appli
assess
product
stabil
review
specif
discuss
protein
oxid
potenti
issu
produc
assess
stabil
biolog
protein
oxid
detriment
impact
activ
stabil
safeti
singh
cours
oxid
one
mani
potenti
product
degrad
pathway
must
consid
oxid
rais
potenti
concern
grft
cervicovagin
compart
lesser
extent
anal
compart
potenti
rout
administr
microbicid
maintain
hydrogen
peroxid
produc
bacteria
zegel
et
al
potenti
oxid
upon
deliveri
necessari
monitor
oxid
level
activ
pharmaceut
ingredi
api
formul
product
subject
sampl
deliveri
review
focus
product
qualiti
character
grft
therefor
focu
api
provid
conting
plan
reason
deal
protein
oxid
event
grft
demonstr
oxid
issu
first
product
evalu
clinic
topic
formul
design
rectal
use
yet
submit
investig
new
drug
ind
applic
fda
say
definit
present
accept
agenc
articl
detail
regulatori
effort
date
therefor
author
request
regulatori
posit
taken
articl
read
opinion
practic
known
accept
fda
hiv
microbicid
grft
target
use
individu
hiv
exposur
hiv
popul
found
countri
poor
commun
develop
countri
therefor
cost
good
microbicid
sensit
issu
reduc
product
cost
turn
reduc
price
per
dose
grft
expand
avail
grft
area
highest
hiv
burden
end
need
better
understand
product
cost
grft
mani
theoret
studi
perform
examin
cost
good
multipl
product
demonstr
econom
feasibl
pmp
show
econom
product
process
scale
depend
tuse
et
al
walwyn
et
al
success
commerci
product
depend
perform
preclin
clinic
trial
safeti
efficaci
howev
practic
issu
regard
avail
sexual
health
product
substanti
popul
potenti
user
conting
cost
driven
part
product
process
therefor
continu
optim
product
process
may
necessari
certainli
purif
process
improv
tremend
group
fuqua
et
al
optim
technolog
need
undertaken
econom
primari
concern
put
forth
review
potenti
express
system
test
opinion
econom
impact
process
chang
may
cost
good
acknowledg
success
develop
grft
hiv
microbicid
depend
sole
clinic
perform
long
hurdl
relat
bulk
pmp
product
overcom
proper
foresight
experi
product
grft
primarili
use
promot
rtmv
transient
express
system
fuqua
et
al
mccormick
et
al
okeef
et
al
shivprasad
et
al
proven
scalabl
issu
transient
express
grft
n
benthamiana
use
rtmv
done
use
nake
infecti
rna
transcrib
plasmid
use
first
passag
viru
particl
isol
plant
scale
reproduc
method
use
first
passag
virion
product
tmv
virion
manufactur
requir
qualif
contain
genom
rtmv
continu
assess
plasmid
virion
durat
manufactur
process
develop
program
monitor
stabil
qualiti
virion
life
grft
product
provid
stabil
activ
data
storag
dna
contain
promot
infecti
sequenc
upstream
coat
protein
promot
behind
n
benthamiana
sequenc
grft
clone
rtmv
vector
design
shivprasad
et
al
use
heterolog
tobacco
mild
green
mosaic
viru
sequenc
coat
protein
cistron
utr
figur
sequenc
direct
larg
amount
dna
purifi
use
plasmid
prep
result
purifi
plasmid
aliquot
deem
plasmid
bank
plasmid
bank
qualifi
sequenc
comparison
abil
produc
virion
particl
grft
plasmid
bank
express
assess
planta
transcrib
dna
rna
use
rna
transcript
kit
subsequ
infect
plant
nake
rna
mccormick
et
al
okeef
et
al
infect
plant
inspect
symptom
specifi
harvest
time
qualif
metric
requir
inocul
plant
show
visibl
symptom
figur
b
plant
harvest
immunosorb
assay
elisa
use
quantifi
produc
grft
protein
green
juic
homogen
okeef
et
al
qualif
inoculum
infect
plant
produc
grft
excess
mgkg
biomass
failur
plasmid
match
origin
sequenc
failur
transcrib
plasmid
induc
signific
symptomolog
inocul
plant
failur
reach
target
express
concentr
grft
disqualifi
plasmid
bank
entireti
requir
bank
product
initi
qualif
plasmid
bank
store
place
stabil
monitor
program
tabl
stabil
monitor
program
plasmid
bank
includ
monitor
sequenc
stabil
function
sequenc
stabil
monitor
sequenc
grft
sequenc
within
plasmid
function
monitor
transcrib
plasmid
assur
nake
tmv
rna
remain
infecti
use
infect
metric
symptomolog
assum
plasmid
bank
remain
stabl
year
need
valid
empir
use
propos
method
understand
plasmid
bank
might
fail
success
product
qualif
plasmid
bank
use
transcrib
infecti
rna
inocul
number
plant
determin
base
size
bank
produc
final
virion
volum
approxim
harvest
biomass
plant
harvest
rel
earli
normal
product
process
approxim
day
infect
virion
amplifi
plant
tissu
extract
isol
concentr
use
modifi
polyethylen
glycol
precipit
procedur
store
asurmendi
et
al
approxim
concentr
virion
determin
uv
absorpt
nm
extinct
coeffici
kathiria
et
al
isol
virion
qualifi
use
function
assess
applic
ng
viru
per
plant
mild
abras
kathiria
et
al
function
assess
display
symptom
characterist
rtmv
vector
infect
grft
express
level
criteria
requir
nake
rna
symptomat
plant
mgkg
grft
comparison
prior
work
tmv
electron
microscopi
imag
use
visual
tmv
particl
data
compar
histor
inform
regard
tmv
virion
size
figur
upon
qualif
virion
bank
stabil
program
implement
tabl
stabil
program
mirror
qualif
program
carri
period
virion
bank
store
inoculum
stabil
program
discuss
herein
use
pmp
express
rtmv
system
stabil
program
complet
better
understand
viabil
plasmid
virion
bank
cogniz
problem
method
scalabl
technolog
transfer
inevit
chang
research
set
optim
purif
process
grft
pilot
product
scale
kentucki
bioprocess
inc
owensboro
ky
usa
facil
cgmp
manufactur
occur
enabl
seamless
process
pilot
scale
product
assess
feasibl
limit
process
import
understand
yield
properli
plan
studi
process
optim
therefor
necessari
initi
step
bulk
product
prior
develop
document
analyt
necessari
proper
cgmp
product
cgmp
requir
develop
valid
product
releas
assay
prove
accept
critic
product
paramet
ident
puriti
potenc
safeti
qualiti
establish
character
stabil
test
qualiti
paramet
establish
repeat
measur
multipl
batch
current
releas
criteria
grft
includ
visual
appear
molecular
weight
determin
mass
spectrometri
ph
determin
solut
protein
concentr
determin
puriti
determin
liquid
chromatographi
potenc
determin
elisa
safeti
determin
endotoxin
level
bioburden
residu
tmv
determin
infect
titter
local
lesion
host
n
tabacum
cv
glurk
decis
regard
accept
bioburden
endotoxin
level
inform
dosag
form
dosag
regim
rout
administr
fda
guidanc
state
calcul
method
describ
unit
state
pharmacopeia
monograph
usp
associ
advanc
medic
instrument
aami
standard
appropri
establish
endotoxin
limit
product
us
depart
health
human
servic
food
drug
administr
unfortun
specif
benchmark
standard
guidanc
bioburden
rectal
product
administr
provid
regulatori
agenc
although
usp
chapter
propos
issu
usp
guidelin
chapter
microbiolog
attribut
nonsteril
pharmaceut
product
provid
specif
guidanc
topic
prepar
specifi
signific
microorgan
nonsteril
pharmaceut
product
evalu
term
use
product
natur
product
potenti
hazard
user
unit
state
pharmacopeia
convent
help
note
maximum
total
aerob
microbi
count
tamc
rectal
administ
product
specifi
world
health
organ
intern
pharmacopoeia
well
european
pharmacopoeia
cfug
cfuml
maximum
total
combin
yeast
mould
count
tymc
cfug
cfuml
european
director
qualiti
medicin
healthcar
world
health
organ
rectum
notabl
nonsteril
biolog
compart
test
therefor
includ
rectal
grft
cofa
inform
like
actual
accept
criterion
tabl
detail
current
qualiti
profil
grft
bulk
api
use
releas
grft
manufactur
cgmp
stabil
test
includ
method
requir
releas
use
inform
common
method
includ
potenc
elisa
monitor
physic
degrad
aggreg
function
stabil
ie
affin
respect
viabl
microbicid
product
grft
must
shelf
life
least
year
therefor
design
stabil
program
tabl
monitor
chemic
physic
thermal
function
stabil
grft
specif
oxid
aggreg
degrad
melt
temperatur
potenc
grft
evalu
current
complet
month
stabil
includ
grft
api
store
room
temperatur
detect
chang
measur
aspect
grft
api
figur
highlight
data
gener
month
stabil
time
point
method
develop
standard
oper
procedur
sop
product
releas
grft
well
monitor
physic
stabil
sop
transfer
kentucki
bioprocess
inc
facil
capabl
cgmp
product
grft
assay
criteria
grft
nativ
dimer
must
show
puriti
retent
time
dimer
must
within
confid
interv
refer
standard
grft
three
independ
run
dynam
method
show
puriti
grft
api
well
monitor
aggreg
degrad
grft
figur
show
grft
pure
month
shelf
life
stabil
assess
detect
aggreg
degrad
grft
anoth
analyt
assay
develop
grft
product
releas
monitor
stabil
potenc
valid
assay
ensur
activ
grft
specif
grft
bind
recombin
envelop
glycoprotein
sole
respons
grft
activ
verifi
elisa
data
figur
demonstr
grft
function
activ
bind
nanomolar
rang
month
grft
lost
potenc
valid
bind
activ
grft
surfac
plasmon
reson
spr
employ
determin
equilibrium
dissoci
constant
k
figur
averag
k
grft
found
nm
month
grft
store
room
temperatur
rt
k
valu
nm
respect
thu
signific
loss
grft
bind
month
storag
anoth
paramet
highlight
thermost
grft
differenti
scan
fluorimetri
dsf
use
determin
melt
temperatur
grft
figur
month
storag
rt
signific
chang
therefor
confirm
structur
integr
grft
lastli
although
discuss
concentr
grft
determin
puriti
monom
speci
monitor
reduc
unalt
month
storag
critic
area
therapeut
protein
develop
relat
storag
product
often
overlook
laboratori
scale
amino
acid
modif
protein
product
includ
oxid
deamid
glycat
progress
modif
protein
time
becom
increasingli
problemat
ident
api
fix
particularli
modif
affect
product
safeti
andor
efficaci
oxid
pmp
occur
planta
product
storag
upon
contact
biolog
fluid
mix
nonoxid
oxid
product
like
seen
fda
degrad
product
impur
fda
requir
impur
character
presenc
oxid
product
may
also
rais
concern
regard
immunogen
chirino
et
al
singh
propens
biopharmaceut
oxid
could
complic
requir
pharmacolog
toxicolog
studi
may
necessit
evalu
toxic
oxid
nonoxid
product
well
gener
stabil
activ
profil
homogen
heterogen
product
oxid
product
therefor
identifi
character
earli
develop
process
avoid
addit
risk
time
econom
cost
bridg
studi
sever
option
handl
presenc
oxid
impur
one
option
handl
mix
product
fulli
oxid
api
fulli
oxid
product
produc
test
perform
ensur
product
fulli
oxid
leav
nonoxid
form
impur
oxid
product
alter
activ
oxid
product
form
aggreg
oxid
product
perform
adequ
vivo
safeti
studi
rather
fulli
oxid
entir
molecul
api
protect
oxid
formul
excipi
design
inhibit
oxid
even
site
direct
mutagenesi
relev
amino
acid
residu
assum
neg
impact
product
activ
perform
molecul
design
import
factor
address
heterogen
product
stabil
issu
well
improv
immunogen
profil
product
singh
methionin
cystein
tryptophan
commonli
oxid
amino
acid
gener
detail
protein
structur
use
guid
identifi
expos
amino
acid
protect
oxid
requir
addit
excipi
formul
add
anoth
layer
complex
direct
modif
amino
acid
sequenc
requir
confirm
activ
structur
stabil
safeti
potenti
modif
manufactur
process
work
grft
protein
oxid
continu
potenti
concern
amino
acid
sequenc
contain
multipl
potenti
oxidiz
amino
acid
figur
scale
manufactur
conjunct
storag
variabl
gener
simul
laboratori
multipl
conting
plan
discuss
preliminari
data
collect
effort
preemptiv
resolv
issu
relat
oxid
grft
altern
amino
acid
sequenc
reduc
number
oxidiz
amino
acid
develop
would
provid
oxid
resist
formul
address
oxid
protect
develop
option
develop
concurr
conting
oxid
need
altern
api
formul
establish
field
success
clinic
develop
requir
issu
oxid
resolv
grft
use
hiv
microbicid
set
target
demograph
individu
high
risk
hiv
exposur
mani
individu
set
therefor
analysi
bulk
grft
product
cost
paramount
system
tout
econom
advantag
compar
tradit
cell
cultur
product
system
reason
includ
low
upstream
cost
eas
scalabl
lack
adventiti
anim
pathogen
econom
advantag
howev
yet
proven
practic
publish
studi
appreci
extent
walwyn
et
al
cost
manufactur
protein
associ
downstream
process
specif
purif
analyt
downstream
cost
scrutin
care
earli
econom
analys
system
gener
estim
account
cost
good
except
may
appli
product
involv
signific
downstream
process
consider
upstream
downstream
process
cost
independ
variabl
lead
assumpt
optim
express
system
would
littl
impact
cost
good
fischer
et
al
wilken
nikolov
theoret
lack
impact
upstream
measur
overal
cost
good
limit
investig
compar
studi
multipl
express
system
howev
upstream
methodolog
impact
downstream
process
cost
multipl
effect
overal
chang
upstream
express
methodolog
could
result
signific
investig
limit
time
necess
immedi
grft
product
upstream
express
technolog
agrobacterium
infiltr
agroinfiltr
transient
express
stabl
transgen
express
method
could
reduc
cost
increas
yield
per
biomass
reduc
complex
downstream
process
express
system
requir
reduc
biomass
process
similar
yield
signific
effect
buyel
fischer
demonstr
reduc
amount
materi
process
harvest
specif
leav
signific
impact
reduc
total
process
volum
reduc
downstream
process
cost
buyel
fischer
express
technolog
provid
significantli
higher
yield
per
biomass
potenti
reduc
upstream
downstream
process
addit
express
technolog
reduc
need
downstream
process
substanti
impact
overal
cost
good
exampl
transgen
plant
would
modest
impact
upstream
cost
remov
continu
need
transient
express
system
potenti
simplifi
downstream
process
limit
transient
express
contamin
tmv
coat
protein
system
endotoxin
system
cost
assess
pmp
product
upstream
downstream
cost
fix
rel
upstream
process
significantli
influenc
downstream
cost
current
multipl
system
use
produc
grft
plant
transplastom
amongst
other
fuqua
et
al
hahn
et
al
okeef
et
al
vafae
et
al
transgen
line
induc
express
system
provid
interest
new
potenti
optim
upstream
express
cost
werner
et
al
altern
express
system
would
vari
degre
impact
grft
product
cost
target
grft
set
need
reduc
overal
cost
requir
data
multipl
express
system
coupl
optim
purif
methodolog
develop
proper
econom
model
relat
overal
cost
valid
econom
model
relat
cost
grft
necessari
scale
process
verifi
predict
outcom
comparison
pilot
manufactur
scale
commerci
advanc
pmp
us
boost
invest
ten
million
dollar
sever
pmp
facil
dub
blue
angel
defens
advanc
research
project
agenc
darpa
invest
increas
exist
capac
pmp
facil
avail
oper
may
allow
greater
proof
concept
put
econom
advantag
pmp
technolog
larg
scale
exist
facil
allow
perform
econom
studi
optim
pmp
well
abil
provid
therapeut
target
set
et
al
suggest
four
point
maxim
opportun
molecular
pharm
first
priorit
drug
target
relev
develop
countri
hiv
microbicid
grft
meet
criteria
drug
highli
relev
countri
second
suggest
put
forth
ii
develop
partnership
countri
allow
develop
local
expertis
technolog
transfer
grft
progress
current
clinic
develop
plan
begin
explor
pot
ential
manufactur
partner
incom
area
heaviest
burden
hiv
hope
establish
product
region
region
sack
et
al
follow
recent
exampl
council
scientif
industri
research
south
africa
csir
kentucki
bioprocess
inc
collabor
agreement
establish
process
facil
emerg
facil
use
speed
commerci
process
engag
potenti
partner
earli
develop
process
prior
final
process
optim
allow
seamless
technolog
transfer
product
focus
addit
two
point
made
et
al
iii
increas
collabor
regulatori
bodi
iv
promot
social
respons
intellectu
properti
manag
time
develop
grft
difficult
address
concern
regulatori
bodi
yet
queri
intellectu
properti
right
alreadi
establish
overal
valu
propos
point
maxim
signific
product
evid
howev
success
grft
product
need
produc
bulk
scale
develop
countri
conting
upon
success
bulk
product
posit
clinic
outcom
current
infrastructur
outlook
develop
addit
pmp
product
clinic
relev
therapeut
current
favour
much
relat
posit
outcom
clinic
develop
valid
pmp
grft
shown
safe
effect
vivo
vitro
model
warrant
clinic
develop
continu
clinic
develop
grft
bulk
product
system
need
develop
parallel
grft
clinic
develop
uniqu
challeng
associ
develop
everi
protein
biopharmaceut
rel
immatur
pmp
bulk
product
platform
provid
addit
challeng
plant
system
seem
optimum
product
grft
may
relat
inher
stabil
natur
product
red
alga
review
updat
field
challeng
associ
bulk
product
grft
progress
made
address
challeng
system
develop
current
place
monitor
use
express
system
program
qualif
assess
stabil
grft
develop
implement
grft
api
demonstr
stabl
robust
signific
chang
puriti
activ
month
potenti
remain
grft
rectal
microbicid
like
mani
biolog
molecular
heterogen
immunogen
could
becom
issu
either
api
formul
product
upon
deliveri
system
develop
preliminari
data
collect
overcom
issu
relat
oxid
grft
assess
formul
direct
molecular
alter
solut
success
develop
grft
safe
effect
microbicid
current
clinic
trial
necessit
avail
popul
logist
acquir
enough
grft
provid
prophylact
high
risk
hiv
exposur
requir
increas
product
infrastructur
usa
abroad
current
infrastructur
usa
suffici
provid
grft
larg
popul
individu
would
potenti
benefit
therefor
expans
product
infrastructur
current
facil
necessari
along
expans
product
region
heavili
affect
hiv
optim
product
system
grft
provid
platform
econom
analysi
viabil
pmp
comparison
upstream
product
system
although
econom
analysi
product
process
specif
like
grft
would
repres
scenario
nonvaccin
pmp
high
express
level
stabil
potenc
current
indic
topic
deliveri
mean
qualif
assay
may
stringent
inject
kenneth
palmer
member
intrucept
biomedicin
llc
hold
licenc
make
sell
griffithsin
unit
state
public
health
servic
